The treat-to-target A1C approach to control type 2 diabetes and prevent complications

Advances in Therapy

Volumn 24, Issue 3, 2007, Pages 545-559

  White, Russell D ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b TRUMAN MEDICAL CENTER   (United States)

Author keywords

Glycemic index; Insulin; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ARTICLE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG DOSE TITRATION; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

ADULT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 34548105685     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02848777     Document Type: Article

References (56)

1. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
2. Quest Diagnostics. Patients improved diabetes control over 5-year period, but many fail to achieve treatment goal: Quest Diagnostics Health Trends™ Diabetes Report is based on 14.3 million test results from 2001-2005 from the nation's largest database of clinical lab results. Available at: http://www.questdiagnostics.com/brand/business/healthtrends/diabetes/ diabetesreport.html. Accessed August 3, 2006.
3. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349.
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
8. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care. 2006;29(suppl 1):S4-S42.
9. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2002 update. Endocr Pract. 2002;8(suppl 1):40-82.
10. International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: IDF; 2005.
11. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389.
12. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
13. Stratton IM, Alder AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
14. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
15. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
16. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
17. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
18. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
19. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034-2044.
20. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22:374-381.
21. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
22. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab. 2006;8:58-66.
23. Davidson JA, Blonde L, Jellinger PS, Lebovitz HE, Parkin CG. Road map for the prevention and treatment of type 2 diabetes. Available at: http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf. Accessed August 1, 2006.
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711-1721.
25. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006;66:31-49.
26. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
27. Chehade JM, Mooradian AD. Drug therapy: current and emerging agents. In: Sinclair AJ, Finucane P, eds. Diabetes in Old Age. 2nd ed. Chichester: John Wiley & Sons; 2001:199-214.
28. Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab. 2005;31:7-13.
29. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-955.
30. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs. 2005;65:325-340.
31. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125-134.
32. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174-183.
33. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet. 2002;41:1043-1057.
34. Brunelle RL, Llewelyn J, Anderson JH Jr, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care. 1998;21:1726-1731.
35. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000;56:399-403.
36. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997;20:1612-1614.
37. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia. 2006;49:1168.
38. Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17:307-313.
39. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care. 1999;22:1258-1261.
40. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-1112.
41. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-451.
42. Sun P, Wang R, Jacober SJ. Therapeutic effectiveness of two insulin regimens for insulin naive patients with type 2 diabetes mellitus: once-daily basal insulin or twice-daily premixed insulin. Diabetes. 2006;55(suppl 1). Abstract 101.
43. Riddle MC. Making the transition from oral to insulin therapy. Am J Med. 2005;118(suppl 5A): 14S-20S.
44. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:9S-18S.
45. Yki-Jarvinen H. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Eur J Clin Invest. 2004;34:410-416.
46. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes. 1995;44:165-172.
47. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885.
48. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70:489-500.
49. Bohannon NJ. Insulin delivery using pen devices: simple-to-use tools may help young and old alike. Postgrad Med. 1999;106:57-64,68.
50. Bohannon NJ, Ohannesian JP, Burdan AL, Holcombe JH, Zagar A. Patient and physician satisfaction with the Humulin®/Humalog® Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther. 2000;22:1049-1067.
51. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes [published correction appears in Diabetes Res Clin Pract. 2006;72:112]. Diabetes Res Clin Pract. 2004;66:193-201.
52. Liebl A, Prager R, Kaiser M, Binz K, Gallwitz B. Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: the PREFER study. Diabetes. 2006;55(suppl 1). Abstract 123.
53. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care. 2002;25:1691-1698.
54. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1999;130:389-396.
55. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:182-188.
56. Rosenstock J, Davies M, Home PD, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes. 2006;55(suppl 1). Abstract 132.